Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for recurrent IDH-mutated high-grade gliomas (POLA network) phase II
2017-004140-38Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 6-months Progression-Free Survival (PFS) by RANO. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on 2017-004140-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004140-38.